Manufacturing, Marketing And Distribution Agreements Between Biotech And Pharmaceutical Companies: Feb. 20 - April 21, 2004#
Biotech Co.* (Country; Symbol) | Pharma Co. (Country) | Product | Terms/Details (Date) |
| | |||
Alliance Pharmaceutical Corp. (OTC BB:ALLP) | IL Yang Pharmaceutical Co. Ltd. (South Korea) | IL Yang got exclusive rights to distribute and commercialize Oxygent in South Korea | Alliance would get royalties from sales of the blood substitute, and milestones for regulatory progress in the U.S. and Europe (4/19) |
Amylin Pharmaceuticals Inc. (AMLN) | Reliant Pharmaceuticals Inc. | Amylin will co-promote Reliant's products for cholesterol management and hypertension | The deal is expected to allow Amylin to leverage its sales efforts in diabetes; terms were not disclosed (4/8) |
Artus GmbH* (Germany) | Abbott Laboratories | Expanded Abbott's distribution rights to all of Artus' nucleic acid-based diagnostics for use on Applied Biosystems instruments | Abbott is expanding the menu of tests it offers by adding Artus tests for several infectious diseases, which it will offer on the Applied Biosystems platform (4/14) |
AVAX Technologies Inc. (OTC BB:AVXT) | OPi SAS (France) | Manufacturing alliance between AVAX unit Genopoeitic and OPi unit Opisodia SAS | AVAX is getting $1.5M for each of the next two years under the deal in which products for both companies will be produced (2/24) |
Cartagen Molecular Systems Inc.* | Entest Japan Inc. (Japan) | Deal to develop a market presence for Cartagen's nucleic acid- separation products in Japan | Terms of the deal were not disclosed (3/9) |
Chiral Quest Inc. (OTC BB:CQST) | Strem Chemicals Inc. | Several of Chiral Quest's ligand products | Strem Chemicals was named a distributor of the products (3/8) |
Chromos Molecular Systems Inc. (Canada; TSE:CHR) | Lonza Biologics plc (UK) | Extended agreement providing Lonza nonexclusive access to Chromos' ACE System for evaluation in contract manufacturing | The extension runs to 4Q:04, and carries an option to license Chromos' ACE System with Lonza's GS System for use in cellular protein production (3/30) |
Cobra Bio- manufacturing plc (UK; LSE:CBF) | AstraZeneca plc (UK) | Cobra will supply Astra- Zeneca licenses to DNA manufacturing technology | AstraZeneca will use the technology in support of identification and evaluation of drug targets; terms were not disclosed (3/30) |
Diversa Inc. (DVSA) | Fermic SA de CV (Mexico) | Fermic will provide manufacturing capacity for production of Diversa's enzyme products | Diversa will co-invest in certain capital equipment in exchange for credits for manufacturing services; specific terms of the long-term deal were not disclosed (2/23) |
EraGen Biosciences Inc.* | Inter Medico (Canada) | Inter Medico will distribute EraGen's molecular diagnostic products in Canada | Inter Medico's rights are exclusive in Canada; terms were not disclosed (3/15) |
GlycoFi Inc.* | Eli Lilly and Co. | Deal to evaluate GlycoFi's yeast-based platform for producing an undisclosed protein | Lilly will support the effort; terms of the deal were not disclosed (4/8) |
GTC Biotherapeutics Inc. (GTCB) | Laureate Pharma LP | Companies will coordinate efforts to provide recombinant protein production services | No initial payments were made in the deal, terms of which were not disclosed (3/9) |
Immtech International Inc. (AMEX:IMM) | Cambrex Charles City Inc. | Agreement for Cambrex to develop an enhanced process for manufacturing DB289, a Phase II drug in malaria and other infectious diseases | Cambrex is expected to manufacture the substance in bulk after developing the synthesis method; terms were not dis- closed (3/17) |
Interleukin Genetics Inc. (OTC BB:ILGN) | Access Business Group International LLC (subsidiary of Alticor Inc.) | Distribution agreement for DNA- ased risk-assessment tests | The deal with Access triggered a $2M payment from Alticor to Interleukin Genetics under a deal they entered in March 2003 (3/16) |
Jerini AG* (Germany) | Bachem AG (Switzerland) | Agreement for the production and supply of Jerini's Icatibant, a peptidomimetic in Phase II | Bachem will provide manufacturing services for the bradykinin antagonist under undisclosed terms (3/18) |
Labopharm Inc. (Canada; TSE:DDS) | Hexal AG (Germany) | Hexal gets the the right to market Labopharm's formulation of tramadol in Germany | Labopharm is responsible for obtaining regulatory approval in Germany; terms of the revenue-sharing deal were not disclosed (3/31) |
Large Scale Biology Corp. (LSBC) | Sigma-Aldrich Fine Chemicals | Manufacturing and distribution deal for LSBC's plant-produced recombinant aprotinin product Apronexin | LSBC will manufacture the protease inhibitor and Sigma-Aldrich will distribute it to the R&D, cell culture and manufacturing markets under the multiyear deal (3/4) |
Ligand Pharmaceuticals Inc. (LGND) | NV Organon (the Netherlands) | Companies will expand their sales efforts related to the pain drug Avinza | They will increase sales calls 50% and establish a specific effort to cover the long-term care/hospice segment of the market (3/31) |
Ligand Pharmaceuticals Inc. (LGND) | Hollister-Stier Laboratories LLC | Hollister-Stier will provide fill/ finish work for Ontak and a second- generation formulation | The five-year deal was made with Ligand subsidiary Seragen Inc., and can be extended two years by Ligand; terms were not disclosed (3/3) |
Ligand Pharmaceuticals Inc. (LGND) | Cardinal Health Inc. | Cardinal will manufacture and package Ligand's Avinza | Ligand has an option to extend the five- year deal two additional years; terms were not disclosed (3/3) |
Microbia Inc.* | Teva Pharmaceutical Industries Ltd. (Israel) | Multiyear, multiproduct expansion of deal to develop improved biomanufacturing processes | The deal centers on Microbia's Precision Engineering technology; Teva will fund Microbia's efforts and make undisclosed milestone and royalty payments (3/29) |
Micromet AG* (Germany) | Boehringer Ingelheim GmbH (Germany) | Deal for the process development and production of Micromet's fully human MT201 antibody | BI will supply material for clinical trials and future commercialization for the Phase II prostate cancer product; Micromet may license BI's high- xpression technology for manufacturing MT201, while BI gets an option for commercial manufacturing of MT201 (2/25) |
NeoPharm Inc. (NEOL) | Diosynth Biotechnology (unit of Akzo Nobel NV) | Diosynth will manufacture interleukin-13-PE38QQR for NeoPharm's Phase III trials | The drug is being tested in glioblastoma multiforme; terms of the deal were not disclosed (4/7) |
NovImmune SA* (Switzerland) | Lonza Group AG (Switzerland) | Deal for the production and supply of clinical-grade monoclonal antibody drugs | Lonza will manufacture the products of NovImmune and its partners, all the way to marketing; terms were not disclosed (2/20) |
Provalis plc (UK; LSE:PRO) | Edmond Pharma SpA (Italy) | Deal for Provalis to distribute the mucolytic agent Erdotin in the UK and Ireland | Provalis is paying €200,000 toward development and regulatory costs, against certain regulatory milestones; the product has been available in other Eurpopean markets (4/19) |
Raven Biotechnologies Inc.* | AppTec Laboratory Services Inc. | Deal for process development and manufacturing of Raven's RAV12 monoclonal antibody | The deal gives Raven flexibility regarding preclinical and future clinical supplies of the cancer product; terms were not dis- closed (4/14) |
RNAx GmbH* (Germany) | Funakoshi Ltd. (Japan) | Funakoshi will be exclusive agent for RNAx in Japan | The deal relates to RNAx services for validation of siRNA oligonucleotides and genetic targets based on RNAi technology (3/26) |
Seattle Genetics Inc. (SGEN) | Abbott Laboratories | Deal for the manufacturing of Seattle Genetics' SGN-30 monoclonal antibody product | Abbott will perform scale-up and GMP manufacturing for trials, and would supply commercial-grade material to support any sales; terms were not disclosed. (2/24) |
Y's Therapeutics (Japan) | Lonza Group Ltd. (Switzerland) | Collaboration on cell line construction of a humanized monoclonal antibody for Y's YSCMA program in cancer and immune diseases | Y's gets access to Lonza's GS Gene Expression System for creating a cell line and to antibody manufacturing expertise; terms were not disclosed (4/6) |
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AMEX = American Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. | |||